Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Pediatric antihypertensive trial failures: analysis of end points and dose range.

Benjamin DK Jr, Smith PB, Jadhav P, Gobburu JV, Murphy MD, Hasselblad V, Baker-Smith C, Califf RM, Li JS.

Hypertension. 2008 Apr;51(4):834-40. doi: 10.1161/HYPERTENSIONAHA.107.108886.

2.

The management of hypertension in African Americans.

Ferdinand KC, Armani AM.

Crit Pathw Cardiol. 2007 Jun;6(2):67-71. Review.

PMID:
17667868
3.

A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension.

Hogg RJ, Delucchi A, Sakihara G, Wells TG, Tenney F, Batisky DL, Blumer JL, Vogt BA, Lo MW, Hand E, Panebianco D, Rippley R, Shaw W, Shahinfar S.

Pediatr Nephrol. 2007 May;22(5):695-701.

PMID:
17216247
4.

Racial differences are seen in blood pressure response to fosinopril in hypertensive children.

Menon S, Berezny KY, Kilaru R, Benjamin DK Jr, Kay JD, Hazan L, Portman R, Hogg R, Deitchman D, Califf RM, Li JS.

Am Heart J. 2006 Aug;152(2):394-9.

PMID:
16875928
5.

Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin.

Woodiwiss AJ, Nkeh B, Samani NJ, Badenhorst D, Maseko M, Tiago AD, Candy GP, Libhaber E, Sareli P, Brooksbank R, Norton GR.

J Hypertens. 2006 Jun;24(6):1057-64.

PMID:
16685205
6.

Systematic review: antihypertensive drug therapy in black patients.

Brewster LM, van Montfrans GA, Kleijnen J.

Ann Intern Med. 2004 Oct 19;141(8):614-27. Review.

PMID:
15492341
7.

Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?

Li JS, Berezny K, Kilaru R, Hazan L, Portman R, Hogg R, Jenkins RD, Kanani P, Cottrill CM, Mattoo TK, Zharkova L, Kozlova L, Weisman I, Deitchman D, Califf RM.

Hypertension. 2004 Sep;44(3):289-93.

8.

Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial.

Cohn JN, Julius S, Neutel J, Weber M, Turlapaty P, Shen Y, Dong V, Batchelor A, Guo W, Lagast H.

Am J Hypertens. 2004 Feb;17(2):134-8.

PMID:
14751655
9.

A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension.

Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S.

Am J Hypertens. 2003 Oct;16(10):795-800.

PMID:
14553956
10.

Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment.

Blumer JL, Daniels SR, Dreyer WJ, Batisky D, Walson PD, Roman D, Ouellet D.

J Clin Pharmacol. 2003 Feb;43(2):128-32.

PMID:
12616664
11.

Oral antihypertensive trial design and analysis under the pediatric exclusivity provision.

Pasquali SK, Sanders SP, Li JS.

Am Heart J. 2002 Oct;144(4):608-14.

PMID:
12360155
12.

A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension.

Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, Shahinfar S; Enalapril Pediatric Hypertension Collaborative Study Group..

J Clin Pharmacol. 2002 Aug;42(8):870-80.

PMID:
12162469
13.

Angiotensinogen gene polymorphism at -217 affects basal promoter activity and is associated with hypertension in African-Americans.

Jain S, Tang X, Narayanan CS, Agarwal Y, Peterson SM, Brown CD, Ott J, Kumar A.

J Biol Chem. 2002 Sep 27;277(39):36889-96.

14.

The pharmacokinetics of enalapril in children and infants with hypertension.

Wells T, Rippley R, Hogg R, Sakarcan A, Blowey D, Walson P, Vogt B, Delucchi A, Lo MW, Hand E, Panebianco D, Shaw W, Shahinfar S.

J Clin Pharmacol. 2001 Oct;41(10):1064-74.

PMID:
11583474
15.

Angiotensin-converting enzyme inhibitors.

Brown NJ, Vaughan DE.

Circulation. 1998 Apr 14;97(14):1411-20. Review.

16.
Items per page

Supplemental Content

Support Center